02. Isotope-related News Department of Energy to Provide $2 Million for Studies to Accelerate the Evaluation of Novel, Medically Relevant Isotopes for Use in Pre-clinical and Clinical Medical Trials The U.S. Department of Energy (DOE) announced up to $2 million in new funding to support translational research and development (R&D) of novel, medically relevant isotopes to accelerate evaluation for usage in pre-clinical and clinical trials. The new funds will be provided as part of a key federal program that produces critical radioisotopes otherwise unavailable or in short supply for U.S. science, medicine, national security, and industry, known as the DOE Isotope Program. To read more please visit: https://www.energy.gov/science/articles/department-energy-provide-2-millionstudies-accelerate-evaluation-novel-medically Source: U.S. Department of Energy, Office of Science
NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67) Exclusively to Clarity Pharmaceuticals for its Targeted Copper Theranostics Programs Cu-67 is a beta-emitting radioisotope with clinical applications as a radiopharmaceutical to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients . NorthStar Medical Radioisotopes, LLC, a global company engaged
in the development,
production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, today
WORLD COUNCIL ON ISOTOPES
8
